Genotoxicity Testing: Market Size & Forecast 2026

The global genotoxicity testing market sits at approximately USD 1.6 billion in 2025 (base year), growing at a 9.5% CAGR through 2032 to reach roughly USD 3.0 billion [Claight estimate: segment-weighted build from 6 end-use categories]. The market is structurally balanced between GLP-regulated in vitro assay demand driven by ICH S2(R1) and OECD TG 471/487 requirements, and an accelerating New Approach Methods (NAMs) pipeline that is beginning to shift the in vitro-to-in vivo cost ratio. North America and Europe together account for roughly 70% of current spend, with Asia Pacific the fastest-growing region at 12-14% CAGR [Claight estimate: UN Comtrade HS 3822 mirror flows + regional pharma R&D indices]. > **Analyst Take.** The 9.5% consensus CAGR is directionally right but compositionally wrong: the in vivo segment is closer to 2-3% CAGR while NAM-anchored in vitro services are growing at

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.